We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic HR positive, HER2 negative breast cancer is a type of breast cancer that has spread to other parts of the body and is characterized by hormone receptor positivity, meaning it grows in response to hormones. This type of cancer does not have excess HER2 protein, which influences treatment options.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.